Recombinant human type IV collagen and preparation method and use thereof

By optimizing the amino acid sequence, recombinant human type IV collagen was efficiently prepared in the Pichia pastoris expression system, solving the problems of high yield and low bioactivity. This resulted in high-yield and high-purity recombinant human type IV collagen with significant skin repair and soothing effects.

CN118440181BActive Publication Date: 2024-11-12XIAN GIANT BIOGENE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410545206.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-30
Publication Date
2024-11-12
Estimated Expiration
2044-04-30

AI Technical Summary

Technical Problem

Existing technologies struggle to provide high-yield, low-cost, and highly bioactive recombinant human type IV collagen, and commercially available products are not effective in skin repair and soothing.

Method used

Using a commercial Pichia pastoris expression system, and through optimized amino acid sequence design, we achieved efficient extracellular secretory expression of recombinant human type IV collagen α2 chain, with a yield of 25.1 g/L. The purity was achieved to 90% through simple ultrafiltration and decolorization, and the resulting product was used to prepare products with repair and soothing effects.

Benefits of technology

It significantly improved the yield and purity of recombinant human type IV collagen, and its effects on skin repair and soothing were superior to commercial products, with good safety and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004822627390000071
    Figure BDA0004822627390000071
  • Figure BDA0004822627390000081
    Figure BDA0004822627390000081
  • Figure BDA0004822627390000091
    Figure BDA0004822627390000091
Patent Text Reader

Abstract

This patent application relates to a recombinant human type IV collagen, a preparation method and a use thereof. The sequence of the recombinant human type IV collagen is shown in SEQ ID No. 1. The recombinant human type IV collagen provided in this patent application has a more significant effect of repairing the skin barrier and soothing, and its amino acid sequence is the amino acid sequence of natural human type IV collagen, and its application to the human body will not produce an immune response. Moreover, the recombinant human type IV collagen can achieve high yield in a conventional commercial expression system.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of bioengineering and relates to a novel recombinant human type IV collagen, a preparation method thereof and a use thereof. Background Art

[0002] Collagen is generally white, transparent, unbranched fibrils, which are the basic support for skin and bones. It is the most abundant type of protein in mammals and an important component of the extracellular matrix. An adult's body contains about 3 kilograms of collagen, accounting for about 25% to 35% of the total protein. It is mainly found in human skin, bones, eyes, teeth, tendons, internal organs (including heart, stomach, intestines, blood vessels), etc. Its function is to maintain the shape and structure of skin and tissues and organs, and it is also an important raw material for repairing damaged tissues.

[0003] The traditional method of producing collagen is to use acid, alkali, and enzymatic methods to treat animal tissues and extract collagen. However, the collagen obtained by the above methods has lost its original biological activity and cannot be used in the biomedical field to play a real role. In addition, animal-derived collagen is difficult to avoid the risks of viral infection and immune rejection. At present, some animal-derived collagen has been used in cosmetics and food, but it is difficult to be widely used in implantable medical devices and tissue engineering products.

[0004] With the continuous innovation and breakthroughs in genetic engineering and synthetic biology, some research institutions at home and abroad have expressed human collagen in vitro through conventional recombinant expression methods, but the production cost is usually too high and the expression yield is low, which cannot meet the needs of industrial mass production. Therefore, the market is in urgent need of a collagen material with an amino acid sequence that is highly homologous to the human body, has excellent biological activity, and can be industrially mass-produced.

[0005] The basement membrane is a specialized extracellular matrix underlying all epithelial cells, endothelial cells, peripheral nerve axons, adipocytes, and muscle cells. Type IV collagen, laminin, globulin, entactin, and type XVII collagen are core basement membrane components. Type IV collagen is mainly present in the basement membrane as an insoluble network. The type IV collagen network is essential for maintaining the basement membrane structure and provides a scaffold for other collagens. Proteolytic remodeling of type IV collagen mediated by matrix metalloproteinases (MMPs)-2, -9, and -14 not only leads to structural changes in the type IV collagen network, but also produces biologically active type IV collagen cryptic fragments. The hidden NC1 domain of the type IV collagen α chain, called soluble type IV collagen, has unique biological functions different from the solid full-length type IV collagen in the basement membrane and has been shown to have potential signaling roles in mesenchymal-endothelial transition (MET), inhibition of certain MMPs, endothelial cell proliferation, fibroblast proliferation and migration, and angiogenesis. Summary of the invention

[0006] In view of the technical problems existing in the above-mentioned prior art, the purpose of the present invention is to provide a new recombinant human type IV collagen with high secretion yield and good repair and soothing effects. A new recombinant human type IV collagen is provided here, which includes a total of 107 amino acids at positions 765-871 of the α2 chain of natural human type IV collagen. Without the need for a special expression system, the secretion yield of the recombinant human type IV collagen in a conventional commercial Pichia yeast expression system can be as high as about 25.1 g / L, and the extracellular secreted protein is basically not degraded during the fermentation process, and a purity of more than 90% can be achieved by simple ultrafiltration and decolorization, which can easily achieve industrial mass production. Moreover, the recombinant human type IV collagen is significantly better than commercial human type IV collagen (Sigma CC076) or other truncated proteins of the α2 chain of human type IV collagen in terms of repairing the skin barrier and soothing.

[0007] The present invention comprises:

[0008] 1. A recombinant human type IV collagen, the amino acid sequence of which is shown in SEQ ID No.: 1.

[0009] 2. A polynucleotide encoding the recombinant humanized type IV collagen according to item 1.

[0010] 3. An expression vector comprising the polynucleotide according to item 2.

[0011] 4. A host cell into which the expression vector described in item 3 is introduced. The host cell may be a prokaryotic cell or a eukaryotic cell, including bacterial hosts such as Escherichia coli, Bacillus subtilis, and Bacillus licheniformis, eukaryotic hosts such as Pichia pastoris, Saccharomyces cerevisiae, animal cells, and plant cells, preferably Escherichia coli and Pichia pastoris, and more preferably Pichia pastoris.

[0012] 5. A method for producing recombinant human type IV collagen as described in item 1, comprising culturing the host cell as described in item 4 to secrete the recombinant human type IV collagen into a culture medium, and separating and purifying the protein in the culture medium to obtain the recombinant human type IV collagen.

[0013] The expression may be one of constitutive expression and induced expression or a combination of the two, wherein the inducer for inducing expression may be an inducer such as IPTG, β-galactoside, methanol, ethanol, etc. The expression strain may be a commonly used genetic engineering bacterial expression host such as Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Bacillus licheniformis, etc., preferably Escherichia coli and Pichia pastoris, more preferably Pichia pastoris.

[0014] 6. The production method according to item 5, wherein the separation and purification adopts one or a combination of methods such as salting out, chromatography, affinity chromatography, acid-base precipitation, membrane separation, etc., preferably a combination of chromatography and membrane separation, and more preferably a combination of ion exchange chromatography and membrane separation.

[0015] 7. Use of the recombinant human type IV collagen according to any one of item 1 in the manufacture of skin care products, health foods, tissue engineering materials, or medical devices.

[0016] 8. Use of the recombinant humanized type IV collagen according to item 1 in the preparation of products with repairing and soothing effects.

[0017] The beneficial effect of the present invention is that: in the technical field, it is generally believed that when a commercial expression host and expression vector are used, the yield of recombinant collagen with a molecular weight of more than 70,000 reaches 10g / L, which is already quite high. The present invention provides a recombinant human type IV collagen with a new amino acid sequence, which is a truncated protein of the α2 chain of human type IV collagen. The yield of the recombinant human type IV collagen expressed by extracellular secretion in a commercial Pichia pastoris expression system can be as high as 25.1g / L, which is significantly higher than the high yield level of recombinant collagen considered in the technical field. The purity of the fermentation product can reach 90% after simple ultrafiltration decolorization. The secretion yield of the recombinant human type IV collagen is significantly better than other truncated proteins of the α2 chain of human type IV collagen. At the same time, the recombinant human type IV collagen is significantly better than commercial human type IV collagen (Sigma CC076) or other truncated proteins of the α2 chain of human type IV collagen in terms of repairing the skin barrier and soothing, and shows good safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The electrophoresis diagram shows the purification results of recombinant collagen type IV-α2.

[0019] Figure 2 The electrophoresis diagram shows the purification results of control proteins IV-1, IV-2 and IV-3.

[0020] Figure 3 Epidermal thickness detection of 3D epidermal model (HE staining).

[0021] Figure 4 This is an immunofluorescence staining image of transglutaminase 1 (TGM1) in the 3D epidermal model.

[0022] Figure 5 To detect the TNF-α content in the supernatant of LPS-induced macrophage model cells.

[0023] Note: Compared with BC, ###P<0.001; compared with NC, *P<0.05, **P<0.01, ***P<0.001.

[0024] Figure 6 To detect the IL-8 content in the supernatant of LPS-induced macrophage model cells.

[0025] Note: Compared with BC, ###P<0.001; compared with NC, *P<0.05, **P<0.01, ***P<0.001.

[0026] Figure 7 To detect the expression of ET-1 gene in HUVEC model induced by hydrogen peroxide.

[0027] Note: Compared with BC, ###P<0.001; compared with NC, *P<0.05, **P<0.01, ***P<0.001. DETAILED DESCRIPTION

[0028] Example 1 Preparation of recombinant collagen type IV-α2 in a yeast expression system

[0029] 1. Experimental Methods

[0030] 1. Expression vector construction

[0031] (1) Preparation of shuttle plasmid

[0032] According to the amino acid sequence shown in SEQ ID No.1, the codon optimization of the yeast expression system was carried out to obtain the recombinant collagen type IV-α2 gene sequence. The obtained target gene sequence was entrusted to Qingke Biotechnology Co., Ltd. for gene synthesis. The synthesized gene was connected to the pPicZαA plasmid to obtain the pPicZαA-I-α2 plasmid.

[0033] (2) Preparation of yeast expression strains

[0034] pPicZαA-I-α2 was linearized with Pme I and then transformed into Pichia pastoris X-33 competent cells. Bleomycin resistance was used as a selection marker to screen transformants to obtain a yeast expression strain.

[0035] 2. Induced expression of target protein

[0036] (1) Pick a single colony of the constructed yeast expression strain and add it to 10 ml of YPD liquid medium (1% yeast extract, 2% peptone and 2% glucose), and culture it at 30°C and 250 rpm for 48 h for activation;

[0037] (2) Transfer the inoculum to a 500 ml Erlenmeyer flask (containing 200 ml of YPD culture medium) at a 2% inoculum volume and culture at 30°C and 250 rpm for 24 h to serve as seeds for the tank.

[0038] (3) Prepare 7 L of BSM medium and add it to a 10 L fermenter, sterilize at 121° C. for 20 min, cool to 30° C., adjust the pH to 5.5, and add the seeds prepared in (2) to the fermenter by flame inoculation for fermentation;

[0039] (4) Cultivate until OD 600 When the OD is 65, 50% glycerol is added until the 600 When the temperature reaches about 120, stop adding, and wait until the dissolved oxygen rebounds to 100%, then start adding methanol for induction;

[0040] (5) During the induction process, the dissolved oxygen was controlled to be not less than 30% and the pH was about 5.5. The induction was continued for 45 h, and the fermentation was terminated. The culture medium was centrifuged at 12,000 rpm for 3 min, and the supernatant was taken for detection of protein yield using the BCA method.

[0041] 3. Collagen purification

[0042] The collected supernatant was passed through a 3KD ultrafiltration membrane and then through a hollow fiber column and freeze-dried to obtain recombinant human type IV collagen (IV-α2). 10 mg of freeze-dried collagen was taken and 10 mL of ultrapure water was added until completely dissolved to prepare a recombinant collagen solution. 10 μL of the recombinant collagen solution was taken and the protein purity was detected by SDS-PAGE.

[0043] 2. Results

[0044] The BCA test result of the recombinant collagen type IV-α2 fermentation tank prepared by the above method is as high as 25.1g / L. The test result of SDS-PAGE electrophoresis method shows that the purity of the protein after ultrafiltration through the hollow fiber column can reach more than 90%. The protein electrophoresis results are as follows: Figure 1 shown.

[0045] Example 2 Preparation of recombinant collagen type IV-α2 control protein in yeast expression system

[0046] The same design concept as recombinant collagen type IV-α2 was used to design protein sequences with similar molecular weights, and the target gene was obtained after codon optimization. After the target gene was fully synthesized, the same shuttle plasmid and host bacteria were used to express the protein sequence. The results of sequence design and expression are shown in the following table (Table 1). Figure 2 This is the electrophoresis diagram of the recombinant collagen type IV-α2 control proteins IV-1, IV-2 and IV-3 after purification provided by the present invention.

[0047] Table 1 Different amino acid sequences and expression results

[0048]

[0049] The results of Examples 1 and 2 show that the yield of the recombinant collagen composed of the amino acid sequence provided by the present invention is much higher than that of other truncated proteins of human type IV collagen α2 with different positions and sizes of similar designs. Therefore, the amino acid sequence provided by the present invention is easier to prepare on a large scale and has greater potential for mass production.

[0050] In the technical field, it is generally believed that when using commercial expression hosts and expression vectors, the yield of recombinant collagen with a molecular weight of more than 70,000 reaches 10g / L, which is already a very high yield. The yield of the recombinant human type IV collagen of the present invention can be as high as 25.1g / L, which is significantly higher than the high yield level of recombinant collagen considered in the technical field.

[0051] Example 3 Skin repairing effect of recombinant collagen type IV-α2

[0052] 1) According to the experimental design in Table 2, the 3D epidermal model was transferred to a 6-well plate (2.0 mL of the model culture medium of the corresponding group was added in advance), and the test group number was marked on the 6-well plate. The plate was incubated in a CO2 incubator (37°C, 5% CO2) for 24 hours.

[0053] 2) Take the prepared working solution of different groups and add it to the model culture medium, refer to the test grouping and corresponding treatment conditions in Table 2, and perform UVB irradiation and drug administration. IV-1, IV-2 and IV-3 are the control proteins of the recombinant collagen type IV-α2 constructed by the present invention, and type IV-Sigma is the human type IV collagen purchased from Sigma-Aldrich (lot number: CC076). The UVB irradiation dose is UVB (500mJ / cm2). After irradiation, replace with fresh culture medium and perform drug administration. The sample to be tested is administered by surface administration. The skin model is collected after 42 hours of treatment in each group.

[0054] 3) The model was removed and embedded after ring cutting, and subjected to transferglutaminase 1 (TGM1) immunofluorescence staining and H&E staining. The model was photographed under a microscope, and the images were collected and analyzed.

[0055] Table 2 Experimental design

[0056]

[0057] The tissue morphology and immunoassay results of the 3D skin model showed that the epidermal thickness and the expression of transglutaminase 1 (TGM1), a protein related to the skin barrier structure, of the sample recombinant collagen type IV-α2 were significantly increased (p<0.01), and the effect was significantly better than that of IV-1, IV-2, IV-3 and IV-Sigma, indicating that recombinant collagen type IV-α2 has better skin repair effects.

[0058] Example 4: Soothing and redness-removing effects of recombinant collagen type IV-α2

[0059] 1. Inhibit inflammatory factors TNF-α and IL-8

[0060] According to the Q / WP-SHACDDTW-WIF-1014LPS-stimulated macrophage inflammatory factor content test specification, the inhibitory effect of recombinant collagen type IV-α2 on macrophage RAW264.7 inflammatory factors TNF-α and IL-8 was detected, and its soothing and redness-removing effect was evaluated.

[0061] 1) Press 1×10 5 The cells were seeded into a 24-well plate at a seeding density of 100 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).

[0062] 2) Liquid preparation: Prepare the test substance working solution according to the experimental design table 3.

[0063] Table 3 Experimental design

[0064]

[0065] 3) Drug administration: When the cell plating rate in the 24-well plate reaches 40% to 60%, group drug administration is carried out.

[0066] 4) LPS stimulation: According to the experimental design, 100 μL of 10×LPS working solution was added to the drug-treated wells, and the wells were shaken left and right to mix the drugs in the wells. The final concentration of LPS was 1 μg / mL, and the cells were cultured in an incubator (37° C., 5% CO 2 ) for 24 h.

[0067] 5) Sample collection: After the incubation is completed, the cell culture supernatant is collected in an EP tube (Note: the amount of collected samples is determined based on the test indicators). After collection, the samples are placed in a -80°C refrigerator for freezing and storage.

[0068] 6) Detection of TNF-α content: Detection was performed according to the operating instructions of the Mouse TNF-α ELISA kit.

[0069] IL-8 content detection: Detection was performed according to the operating instructions of the Mouse IL-8 ELISA kit.

[0070] The experimental results showed that when LPS stimulated macrophages RAW264.7, the secretion of TNF-α and IL-8 in the NC group increased significantly compared with the BC group, and the model was successfully established. Based on the LPS-stimulated macrophage RAW264.7 model, when the concentration of the sample recombinant collagen type IV-α2 was 0.2 mg / mL, the secretion of inflammatory factors TNF-α and IL-8 by macrophages RAW264.7 was significantly reduced, and there was a statistical difference compared with the NC group (p<0.001). The inhibitory effect on inflammatory factors TNF-α and IL-8 was significantly better than IV-1, IV-2, IV-3 and IV-Sigma. The above experimental results show that recombinant collagen type IV-α2 has a better soothing and redness-removing effect.

[0071] 2. Inhibit endothelin 1 (ET-1)

[0072] A hydrogen peroxide-induced human umbilical vein endothelial cell (HUVEC) model was established to detect the inhibitory effect of recombinant collagen type IV-α2 on ET-1 in HUVEC cells and to evaluate its soothing and redness-removing effects.

[0073] 1) Press 2×10 5 The cells were seeded into 6-well plates at a seeding density of 100 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).

[0074] 2) Liquid preparation: Prepare the test substance working solution according to the experimental design table 3.

[0075] Table 3 Experimental design

[0076]

[0077] 3) Sample treatment: When the cell plating rate in the 6-well plate reaches 40% to 60%, the cells are divided and dosed. 2 ml of the test substance working solution is added to the experimental group, and the same volume of cell culture medium is added to the blank control group and the negative control group.

[0078] 4) Hydrogen peroxide stimulation: After the cells were treated with the sample for 24 hours, hydrogen peroxide (final concentration of 200 μM) was added to the negative control and experimental groups for stimulation for 4 hours.

[0079] 5) Extraction of mRNA and reverse transcription: After 24 hours, the culture medium was discarded and the total mRNA was extracted by Trizol method. The RNA concentration was measured by ultra-micro spectrophotometer. The sample was qualified if the concentration was greater than 20 ng / μL and the A260 / A280 value was greater than 1.8. RevertAid TM cDNA was synthesized using the First Strand cDNA Synthesis Kit.

[0080] 6) ET-1 gene expression detection: SYBR Green qPCR Mix, cDNA template, primers (sequences as shown in Table 4) and RNase-free ddH2O were dissolved at 4°C, and the Real-Time PCR reaction system was configured on ice. The PCR reaction was performed using a two-step method, and the reaction program was set up as follows: first step: 95°C pre-denaturation for 300s; second step: 95°C denaturation for 20s, 55°C annealing for 20s, 72°C extension for 20s, and 40 reaction cycles.

[0081] Table 4 Primer sequence list

[0082]

[0083] The experimental results showed that when hydrogen peroxide stimulated human umbilical vein endothelial cells HUVEC, the NC group showed a significant increase in ET-1 gene expression compared with the BC group, indicating a successful modeling. Based on the hydrogen peroxide-stimulated HUVEC cell model, when the sample recombinant collagen type IV-α2 was at a concentration of 0.2 mg / mL, the ET-1 gene expression in HUVEC cells was significantly reduced, and there was a statistical difference compared with the NC group (p<0.001). The inhibitory effect on ET-1 gene expression was significantly better than IV-1, IV-2, IV-3 and IV-Sigma. The above experimental results show that recombinant collagen type IV-α2 has a better soothing and redness-removing effect.

[0084] Sequence information

[0085] SEQ ID No.: 1

[0086] GPPGEGLPG EVLGAQPGPR GDAGVPGQPG LKGLPGDRGP PGFRGSQGMP GMPGLKGQPGLPGPSGQPGL YGPPGLHGFP GAPGQEGPLG LPGIPGREGL PGDRGDP

[0087] SEQ ID No.:2

[0088] GDPGPPGLPA YSPHPSLAKG ARGDPGFPGA QGEPGSQGEP GDPGLPGPPG LSIGDGDQRRGLPGEMGPKG FIGDPGIPALYGGPPGPDGK RGPPGPPGLP GPPGPDGFLF

[0089] SEQ ID No.:3

[0090] GIPGLPGRPG HIKGVKGDIG VPGIPGLPGF PGVAGPPGIT GFPGFIGSRG DKGAPGRAGLYGEIGATGDF GDIGDTINLP GRPGLKGERG TTGIPGLKGF FGEKG

[0091] SEQ ID No.:4

[0092] GDKGAPGIFG LKGYRGPPGP PGSAALPGSK GDTGNPGAPG TPGTKGWAGD

[0093] SGPQGRPGVF GLPGEKGPRG EQGFMGNTGP TGAVGDRGPK GPKGDPGFPG

[0094] APGTVG

Claims

1. A recombinant human type IV collagen, the amino acid sequence of which is shown in SEQ ID No.:

1.

2. A polynucleotide encoding the recombinant human type IV collagen according to claim 1.

3. An expression vector comprising the polynucleotide according to claim 2.

4. A host cell into which the expression vector according to claim 3 has been introduced.

5. A method for producing the recombinant human type IV collagen according to claim 1, comprising culturing the host cell according to claim 4 to secrete the recombinant human type IV collagen into a culture medium, and separating and purifying the protein in the culture medium to obtain the recombinant human type IV collagen.

6. The production method according to claim 5, wherein: The separation and purification adopts one or a combination of salting out, chromatographic chromatography, affinity chromatography, acid-base precipitation and membrane separation.

7. Use of the recombinant human type IV collagen according to claim 1 in the manufacture of skin care products, health foods, tissue engineering materials, or medical devices.

8. Use of the recombinant human type IV collagen according to claim 1 in preparing a product with repairing and soothing effects.